Videos

Eytan Stein, MD and Hetty Carraway, MD, wrap up their discussion with a review of the unmet needs in AML treatment and exciting therapies in the pipeline.

Dr Naveen Pemmaraju discusses the current treatment standards for both polycythemia vera and essential thrombocythemia, highlighting the needs of high-risk patients.

Hetty Carraway, MD, explains the importance of bone marrow biopsies in patients with AML receiving treatment with venetoclax + azacitidine.

Naveen Pemmaraju, MD, provides an overview of the three classes of myeloproliferative neoplasms and the signaling pathways that drive therapeutic investigation in the field.

Hetty Carraway, MD and Eytan Stein, MD, discuss the appropriate strategies for the management of cytopenias in patients with AML on venetoclax + azacitidine treatment.

Siddhartha Mukherjee, MD, discusses potential means of targeting chimeric antigen receptor T-cell therapy for patients with acute myeloid leukemia.

Chenyu Lin, MD, discusses the results of a 10-year follow up of patients who underwent allogenic stem cell therapy with the novel cell therapy omidubicel.

Erika P. Hamilton, MD, discusses how researchers are addressing unmet needs for patients with HER2-positive breast cancer.

Raajit Rampal, MD, PhD, discusses the current treatment landscape for patients with myelofibrosis.

Nicolas Gazeau discusses a retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who have received chimeric antigen receptor T-cell therapy.

In an interview with Targeted OncologyTM Nina Shah, MD, discusses the findings from several trials that show the efficacy of daratumumab for patients with multiple myeloma.

Closing out the program, Dr Gilles Salles highlights currently unmet needs in DLBCL and investigational treatments he finds exciting.

Dr Gilles Salles shares his opinion on the presented case’s treatment decision and the regimen he would have selected for the patient.

Gilles Salles, MD, PhD, explains data on the adverse events seen with the pola-BR regimen in R/R DLBCL during the GO29365 clinical trial.

A review of population, dosing, and efficacy data from the GO29365 clinical trial investigating the combination of polatuzumab, bendamustine, and rituximab (pola-BR) for R/R DLBCL.

Dr Salles provides an overview of the available third-line treatment options for patients with R/R DLBCL who are ineligible for or do not wish to receive autologous stem cell transplant or CAR T-cell therapy.

An oncologist describes the typical major challenges of managing patients with R/R DLBCL and the incidence of relapsed or refractory disease.

Gilles Salles, MD, PhD, presents the case of a 51-year-old woman with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Sam S. Chang, MD, MBA, discusses the methods and design of the QUILT 3032 study.

Jennifer Moss, PhD, discusses challenges that impact community cancer care in rural communities.

Eytan Stein, MD, presents the case of an 81-year-old patient with AML who is unfit for intensive induction therapy for discussion.

Hetty Carraway, MD, highlights the role of venetoclax + azacitidine in the treatment of patients with acute myeloid leukemia who are unfit for intensive induction therapy.

Oncologists share some final thoughts on lutetium-PSMA-617 and novel agents to look out for in prostate cancer treatment.

Evanthia Roussos Torres, MD, PhD, discusses the next steps and novel therapies currently showing promise in the HER-2 negative breast cancer space.

Jesus G. Berdeja, MD, discusses the potential of chimeric antigen receptor T-cell therapy to be approved for earlier lines of treatment in multiple myeloma.

Arndt Vogel, MD, discusses the study results of the IMMUTACE study in hepatocellular carcinoma.

Toni K. Choueiri, MD, discusses results from the KEYNOTE-564 efficacy analysis of adjuvant pembrolizumab in renal cell carcinoma.

David Barrington, MD, discusses the results investigators found in determining treatment patterns and recommendations for patients with endometrial cancer.

Sophia Kamran, MD, discusses future roles that radiation oncology will play in combination with resection and targeted therapy in urothelial carcinoma.

Eytan Stein, MD, continues the discussion of AML treatments with a look at the options for patients with AML and mutations.